Jones Keith Anthony purchased $7K of HUMA

Humacyte (HUMA) reported positive interim Phase 3 trial results for its ATEV in female hemodialysis patients, meeting the primary endpoint. ATEV recipients had more catheter-free days and faster functional access than AV fistula recipients. The company plans to submit a label expansion application to the FDA this quarter. HUMA stock is up 0.31% at $0.41.

Humacyte Inc. (HUMA) reported positive interim results from its V012 Phase 3 trial for a hemodialysis access device, showing superiority over the current standard. The trial was stopped early after meeting its primary endpoint. The company plans to submit an FDA application to expand the device's label. HUMA's stock may be of interest to investors.

Humacyte (HUMA) reported a 44% increase in hospitals ordering its vascular trauma product Symvess, rising to 49 from 34 in Q2 2026. The company expects to exceed its goal of adding 20 new hospitals by year-end. Symvess is FDA-approved for urgent revascularization in adults. Humacyte is also developing other vascular applications.

Humacyte, Inc. (HUMA) plans to submit a supplemental BLA this quarter to expand Symvess's label to AV access for hemodialysis. The company will present interim Phase 3 data for its ATEV at ASN Kidney Week 2026.

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

Humacyte Inc. (HUMA) announced that the FDA extended the shelf life of its Symvess product from 18 to 36 months. The decision was based on stability data showing Symvess meets quality standards. The company's CEO noted the extension supports hospital adoption and reduces product waste. HUMA's stock is currently trading at $0.58, down 1.13%.